The H3N2 virus is spreading rapidly across Delhi and nearby areas of NCR cities, where several people are suffering from common flu-like symptoms. A recent health report released by the Local Circles ...

New research presented at the Annual Meeting of the European Association for the Study of Diabetes in Vienna, Austria (Sept ...

Australia: Researchers have found in a new study that frequent intake of artificially sweetened beverages during pregnancy ...

In a trial comparing two oral GLP-1s, orforglipron was superior to semaglutide for glycemic control and weight loss in ...

Patients on Eli Lilly and Co.’s experimental diabetes pill lost more weight and had better blood sugar control than those on ...

Regeneron Pharmaceuticals said a mid-stage study of its potential obesity treatment found that it could meaningfully preserve muscle mass while enhancing fat loss.

The drug, which is meant to treat Type 2 diabetes, was compared with Novo Nordisk’s oral semaglutide, and showed greater improvements in blood sugar levels, known as A1C, and greater weight loss.

An oral GLP-1 induced significantly greater weight loss than placebo for adults with obesity or overweight plus one ...

In a late-stage trial, an investigational GLP-1 pill from Eli Lilly helped diabetes patients lower their blood sugar and ...

The once-daily oral GLP-1 RA orforglipron produces clinically and statistically significant weight loss and cardiometabolic improvements, with safety comparable to that of injectable agents.

Laser surgery for nearsightedness is as safe and effective in older teenagers as it is in adults, researchers reported on ...

A senior Novo Nordisk executive on Wednesday described the drugmaker's ongoing trial of its blockbuster obesity medicine for ...